The invention relates to a pharmaceutical combination comprised of paclitaxel (Taxol(R)), docetaxel (Taxotere(R)), or derivatives of them, and a cyclin-dependent kinase inhibitor. It also relates to a method of administration of such a combination, where the taxane is given intermittently and the cyclin-dependent kinase is given repeatedly within the same cycle.